Literature DB >> 4566290

A comparison of 5-fluorouracil administered by slow infusion and rapid injection.

C G Moertel, A J Schutt, R J Reitemeier, R G Hahn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4566290

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  10 in total

1.  Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.

Authors:  D Raghavan; J Bishop; D Sampson; J Grygiel; R Woods; A Coates; R Fox
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU).

Authors:  Patricia M LoRusso; Sucharu Prakash; Antoinette Wozniak; Lawrence Flaherty; Mark Zalupski; Anthony Shields; Howard Sands; Ralph Parchment; Bhaskara Jasti
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

3.  The clinical syndrome of 5-fluorouracil cardiotoxicity.

Authors:  J F Ensley; B Patel; R Kloner; J A Kish; J Wynne; M al-Sarraf
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

Review 4.  Should we still be using bolus 5-FU prior to infusional regimens in gastrointestinal cancers? A practical review.

Authors:  Larissa Costa Amorim; Renata D'Alpino Peixoto
Journal:  Int Cancer Conf J       Date:  2021-11-24

5.  5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.

Authors:  Z Bardakji; J Jolivet; Y Langelier; J G Besner; J Ayoub
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 6.  5-Fluorouracil radiation sensitization--a brief review.

Authors:  J E Byfield
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

7.  Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.

Authors:  Hee Yi; Hee-Jung Cho; Soo-Min Cho; Dong-Goo Lee; A M Abd El-Aty; So-Jeong Yoon; Gun-Won Bae; Kwang Nho; Bokyung Kim; Chi-Ho Lee; Jin-Suk Kim; Michael G Bartlett; Ho-Chul Shin
Journal:  BMC Cancer       Date:  2010-05-18       Impact factor: 4.430

8.  A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.

Authors:  G R Weiss; T J Ervin; M W Meshad; D Schade; A R Branfman; R J Bruni; M Chadwick; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

9.  Combination of 5-fluorouracil and N1,N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma cells.

Authors:  Woonyoung Choi; Eugene W Gerner; Latha Ramdas; Jheri Dupart; Jennifer Carew; Lynsey Proctor; Peng Huang; Wei Zhang; Stanley R Hamilton
Journal:  J Biol Chem       Date:  2004-11-16       Impact factor: 5.157

10.  Letter: Blood levels of 5-fluorouracil during intravenous infusion.

Authors:  M Kawai; J Rosenfeld; P McCulloch; B L Hillcoat
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.